Total Funding
58
Total FundingVenture - Series Unknown raised
Growth Score
pts
Heat Score
28 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
Meves Pharmaceuticals is developing nucleoside based therapies for mitochondrial DNA (mtDNA) depletion syndromes.
Joshua Grass: CEO
About the Company
Meves Pharmaceuticals is developing nucleoside based therapies for mitochondrial DNA (mtDNA) depletion syndromes (MDS or MDDS), a category of severe genetic diseases. The initial focus is on therapy tailored specifically to treat patients with Thymidine Kinase 2 (TK2) deficiency, a discrete monogenic disorder associated with profound skeletal
myopathy.
